These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 19148581

  • 1. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.
    Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S, Hasselblatt M, Paulus W, Fuller G, Wolff JE, Gopalakrishnan V.
    J Neurooncol; 2009 Jul; 93(3):303-18. PubMed ID: 19148581
    [Abstract] [Full Text] [Related]

  • 2. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM, Fulda S.
    Oncogene; 2009 Sep 03; 28(35):3097-110. PubMed ID: 19597472
    [Abstract] [Full Text] [Related]

  • 3. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation.
    Moriwaki K, Shinzaki S, Miyoshi E.
    J Biol Chem; 2011 Dec 16; 286(50):43123-33. PubMed ID: 22027835
    [Abstract] [Full Text] [Related]

  • 4. Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5.
    Li Y, Fan X, Goodwin CR, Laterra J, Xia S.
    BMC Cancer; 2008 Nov 07; 8():325. PubMed ID: 18992144
    [Abstract] [Full Text] [Related]

  • 5. Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.
    Bertram H, Nerlich A, Omlor G, Geiger F, Zimmermann G, Fellenberg J.
    Mod Pathol; 2009 Jul 07; 22(7):895-905. PubMed ID: 19305384
    [Abstract] [Full Text] [Related]

  • 6. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, Song N, Teng Y, Liu Y.
    J Cancer Res Clin Oncol; 2012 Aug 07; 138(8):1279-89. PubMed ID: 22447040
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
    Pennarun B, Kleibeuker JH, Oenema T, Stegehuis JH, de Vries EG, de Jong S.
    Anal Cell Pathol (Amst); 2010 Aug 07; 33(5):229-44. PubMed ID: 20978316
    [Abstract] [Full Text] [Related]

  • 8. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
    Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, Kubota T, Yagita H, Koyama-Okazaki T, Sugita K.
    Exp Hematol; 2010 Oct 07; 38(10):885-95. PubMed ID: 20670671
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
    Pennarun B, Kleibeuker JH, Oenema T, Stegehuis JH, de Vries EG, de Jong S.
    Cell Oncol (Dordr); 2011 Jun 07; 34(3):245-59. PubMed ID: 21538027
    [Abstract] [Full Text] [Related]

  • 10. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R, Albarenque SM, Cool RH, Quax WJ, Mohr A, Zwacka RM.
    Cancer Biol Ther; 2014 Jun 07; 15(12):1658-66. PubMed ID: 25482930
    [Abstract] [Full Text] [Related]

  • 11. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 12. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
    Chen S, Fu L, Raja SM, Yue P, Khuri FR, Sun SY.
    Mol Cancer; 2010 Jan 29; 9():23. PubMed ID: 20113484
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.
    Zhu X, Zhang K, Wang Q, Chen S, Gou Y, Cui Y, Li Q.
    Med Oncol; 2015 Apr 29; 32(4):133. PubMed ID: 25796504
    [Abstract] [Full Text] [Related]

  • 14. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
    Bagci-Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K.
    Oncogene; 2013 Jun 06; 32(23):2818-27. PubMed ID: 22824792
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
    Shin D, Kwon HY, Sohn EJ, Nam MS, Kim JH, Lee JC, Ryu SY, Park B, Kim SH.
    Cell Physiol Biochem; 2015 Jun 06; 36(3):1151-62. PubMed ID: 26111475
    [Abstract] [Full Text] [Related]

  • 16. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y, Zhang B.
    Mol Cancer Res; 2008 Dec 06; 6(12):1861-71. PubMed ID: 19074831
    [Abstract] [Full Text] [Related]

  • 17. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM, Pennarun B, Le PT, de Vries EG, de Jong S.
    BMC Cancer; 2011 Jan 27; 11():39. PubMed ID: 21272366
    [Abstract] [Full Text] [Related]

  • 18. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J.
    Exp Cell Res; 2007 Jul 01; 313(11):2378-88. PubMed ID: 17462628
    [Abstract] [Full Text] [Related]

  • 19. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
    Venza I, Visalli M, Oteri R, Teti D, Venza M.
    Int Immunopharmacol; 2014 Aug 01; 21(2):439-46. PubMed ID: 24946096
    [Abstract] [Full Text] [Related]

  • 20. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
    Jaganathan J, Petit JH, Lazio BE, Singh SK, Chin LS.
    Neurosurg Focus; 2002 Sep 15; 13(3):ecp1. PubMed ID: 15844877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.